Companies › Actinium Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Iomab-B Anti-CD117 monoclonal antibody conjugated to iodine-131 | CD117 | Phase 3 | Acute Myeloid Leukemia; Non Hodgkin Lymphoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02665065 | Iomab-B | Phase 3 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT06768905 | Iomab-B | Phase 1 | Non Hodgkin Lymphoma | Oncology | May 2029 |
Cash of $36m on 2026-06-30; operating cash outflow about $22m a year; runway about 20 months at that burn, to Feb 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Immutep S.A.S. Genelux Imunon ADC Therapeutics Candel Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.